Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $10.69 USD
Change Today -0.44 / -3.95%
Volume 1.3M
IMGN On Other Exchanges
As of 8:10 PM 10/6/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

830 Winter Street

Waltham, MA 02451

United States

Phone: 781-895-0600


ImmunoGen, Inc., a biotechnology company, develops targeted anticancer therapeutics. The company develops its products using its antibody-drug conjugates (ADC) technology. The company developed its ADC technology to enable the creation of well-tolerated anticancer products. An ADC with its technology comprises an antibody that binds primarily to an antigen target found on the surface of cancer cells with one of its potent cancer-cell killing agents, or payloads, attached to the antibody using one of its engineered linkers. An ADC compound's antibody component enables it to bind to cancer cells that have its antigen on their surface and the payload agent serves to kill these cancer cells. Wholly Owned Compounds Mirvetuximab Soravtansine The company’s product candidate mirvetuximab soravtansine, or IMGN853, is a folate receptor alpha (a), or FRa,-targeting ADC that is a potential treatment for ovarian cancer and certain other FRa-positive solid tumors. This ADC comprises a FRa-binding antibody with its potent DM4 cell-killing agent attached using one of its engineered linkers. Mirvetuximab soravtansine has been granted orphan drug status for ovarian cancer by the U.S. Food and Drug Administration (FDA). It also has received this designation in the EU. IMGN529 and Coltuximab Ravtansine IMGN529 and coltuximab ravtansine are potential treatments for diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies. IMGN529 includes an ImmunoGen CD37-targeting antibody that, in preclinical testing, demonstrated anticancer activity. DM1 is attached to it using one of its engineered linkers. In a dose-finding Phase 1 clinical trial, initial evidence of anticancer activity was reported with IMGN529, particularly for patients with relapsed/refractory DLBCL. In preclinical models, IMGN529 has demonstrated synergistic activity with the CD20-targeting antibody Rituxan (rituximab). Coltuximab ravtansine, previously called SAR3419, is a CD19-targeting ADC that is a potential new treatment for DLBCL. In Phase 2 clinical testing this ADC had encouraging single-agent activity in the treatment of relapsed/refractory DLBCL. IMGN779 IMGN779 is a potential new treatment for acute myeloid leukemia and myelodysplastic syndrome. It comprises an ImmunoGen CD33-targeting antibody with one of its new DNA-acting payload agents, DGN462, attached using one of its engineered linkers. The company intends to submit an Investigational New Drug (IND) application for it to the FDA. Partners The company’s partners include Amgen Inc.; Bayer HealthCare (a subgroup of Bayer AG); Biotest AG; Eli Lilly and Company, or Lilly; Novartis Institutes for BioMedical Research, Inc., or Novartis; the Roche Group; Sanofi; and Takeda Pharmaceutical Company Limited. Sanofi Collaboration Agreement: In 2003, the company entered into a collaboration agreement with Sanofi (formerly Aventis) to discover, develop and commercialize antibody-based products. The collaboration agreement provides Sanofi with worldwide development and commercialization rights to new antibody-based products directed to targets that are included in the collaboration, including the exclusive right to use its maytansinoid ADC technology in the creation of products directed to these targets. Intellectual Property As of June 30, 2015, the company’s patent portfolio had a total of 659 issued patents worldwide and 645 pending patent applications worldwide. Research and Development As of June 30, 2015, the company spent approximately $111.8 million on research and development activities. History ImmunoGen, Inc. was founded in 1981. The company was incorporated in Massachusetts in 1981.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMGN:US $10.69 USD -0.44

IMGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ablynx NV €11.62 EUR -0.295
Abzena PLC 71.00 GBp 0.00
BioInvent International AB kr2.89 SEK 0.00
Kyowa Hakko Kirin Co Ltd ¥1,742 JPY -58.00
MorphoSys AG €61.60 EUR +0.239
View Industry Companies

Industry Analysis


Industry Average

Valuation IMGN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.3x
Price/Book 27.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUNOGEN INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at